Reduced Rivaroxaban Dose Versus Dual Antiplatelet Therapy After Left Atrial Appendage Closure ADRIFT a Randomized Pilot Study
| Affiliation auteurs | !!!! Error affiliation !!!! |
| Titre | Reduced Rivaroxaban Dose Versus Dual Antiplatelet Therapy After Left Atrial Appendage Closure ADRIFT a Randomized Pilot Study |
| Type de publication | Journal Article |
| Year of Publication | 2020 |
| Auteurs | Duthoit G, Silvain J, Marijon E, Ducrocq G, Lepillier A, Frere C, Dimby S-F, Popovic B, Lellouche N, Martin-Toutain I, Spaulding C, Brochet E, Attias D, Mansourati J, Lorgis L, Klug D, Zannad N, Hauguel-Moreau M, Braik N, Deltour S, Ceccaldi A, Wang H, Hammoudi N, Brugier D, Vicaut E, Juliard J-M, Montalescot G, Investigators ADRIFT |
| Journal | CIRCULATION-CARDIOVASCULAR INTERVENTIONS |
| Volume | 13 |
| Pagination | e008481 |
| Date Published | JUL |
| Type of Article | Article |
| ISSN | 1941-7640 |
| Mots-clés | atrial appendage, Atrial fibrillation, clopidogrel, Rivaroxaban, thrombin |
| Résumé | {Background: Percutaneous left atrial appendage closure (LAAC) exposes to the risk of device thrombosis in patients with atrial fibrillation who frequently have a contraindication to full anticoagulation. Thereby, dual antiplatelet therapy (DAPT) is usually preferred. No randomized study has evaluated nonvitamin K antagonist oral anticoagulant after LAAC, and we decided to evaluate the efficacy and safety of reduced doses of rivaroxaban after LAAC. Methods: ADRIFT (Assessment of Dual Antiplatelet Therapy Versus Rivaroxaban in Atrial Fibrillation Patients Treated With Left Atrial Appendage Closure) is a multicenter, phase IIb study, which randomized 105 patients after successful LAAC to either rivaroxaban 10 mg (R-10 |
| DOI | 10.1161/CIRCINTERVENTIONS.119.008481 |